SCHEMBL17869859

SCHEMBL17869859

O=C(O)c1cnc(N2CCC(O)CC2)o1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.37
CYP2C19 P33261 1/20 0.37
ABL1 P00519 2/20 0.37
GPR119 Q8TDV5 1/20 0.37
AURKA O14965 2/20 0.35
NEK2 P51955 1/20 0.34
CDC7 O00311 1/20 0.34
PLK4 O00444 1/20 0.34
CHEK1 O14757 1/20 0.34
PDPK1 O15530 1/20 0.34
JAK2 O60674 1/20 0.34
ROCK2 O75116 1/20 0.34
PAK4 O96013 1/20 0.34
CHEK2 O96017 1/20 0.34
EGFR P00533 1/20 0.34
NTRK1 P04629 1/20 0.34
PRKCG P05129 1/20 0.34
INSR P06213 1/20 0.34
LCK P06239 1/20 0.34
FYN P06241 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17869798 0.82 ALDH1A1 (0.40) KDM4EJAK2POLBNLRP3AOC3
SCHEMBL31705995 0.81 POLB (0.53) KDM4EPIK3CGPOLBHTTAOC3
SCHEMBL20166106 0.72 RIPK1 (0.69)
SCHEMBL16049350 0.72 CKS1B (0.50) GPR119LMNA
SCHEMBL20165655 0.70 RIPK1 (0.68)
SCHEMBL3436255 0.69 IRAK4 (0.41) KDM4ECYP2C19ABL1GPR119AURKA
SCHEMBL30860648 0.67 KDM4E (0.45) KDM4EAURKAJAK2RPS6KB1MAPK1
SCHEMBL17645995 0.66 TP53 (0.40) LMNAPOLBNLRP3
SCHEMBL14575732 0.66 HRH3 (0.55) KDM4EABL1FGFR1LMNAPOLB
SCHEMBL14575925 0.66 SCD (0.49)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3623372-B1 PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS VALO HEALTH INC (US) 2026-02-04 EP disclosed
EP-3623372-A1 PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS Forma Therapeutics, Inc. (US) 2020-03-18 EP disclosed
EP-3240791-B1 PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS FORMA THERAPEUTICS INC (US) 2019-11-06 EP disclosed
US-9902728-B2 Pyrrolo and pyrazolopyrimidines as ubiquitin-specific protease 7 inhibitors FORMA THERAPEUTICS, INC. (US) 2018-02-27 US disclosed
US-20160185785-A1 PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS VALO HEALTH, INC. 2016-06-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160185785-A1 PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS USP7, UBA7, UBXN1 KDM4E 994/4885CYP2C19 1651/4885ABL1 1555/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.